Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study has been terminated.
(Sponsor wanted study rewritten)
Sponsor:
Collaborators:
National Cancer Institute (NCI)
GlaxoSmithKline
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01550185
First received: March 7, 2012
Last updated: April 4, 2016
Last verified: April 2016
History of Changes
  Purpose
The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded to previous therapy or have suffered a relapse

Condition Intervention Phase
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Recurrent Adult Acute Myeloid Leukemia
 Drug: eltrombopag olamine
Procedure: standard follow-up care
 Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:
  • MTD and tolerability of eltrombopag olamine in patients with AML, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4 [ Time Frame: Up to day 15 ] [ Designated as safety issue: Yes ]
  • Platelet count recovery to >= 100 x 10^9/L when eltrombopag olamine is administered following high dose cytarabine and mitoxantrone for the treatment of AML patients [ Time Frame: Up to 9 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Platelet recovery to >= 100 x 10^9/L and platelet response, assessed based on a modified International Working Group Consensus Criteria for hematologic improvement [ Time Frame: Up to 9 weeks ] [ Designated as safety issue: No ]
    Number of platelet transfusions and duration of time without platelet transfusions from the first dose of eltrombopag olamine will be measured.

  • Platelet response based on a modified International Working Group Consensus Criteria for hematologic improvement [ Time Frame: Up to 9 weeks ] [ Designated as safety issue: No ]
  • Platelet transfusion requirements [ Time Frame: Up to 9 weeks ] [ Designated as safety issue: No ]
Enrollment: 10
Study Start Date: May 2012
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (eltrombopag olamine)
Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
 Drug: eltrombopag olamine
Given PO
Other Names:
  • Promacta
  • SB 497115
  • SB-497115
  • SB497115
Procedure: standard follow-up care
Receive standard care

Detailed Description:

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) and examine the tolerability of daily oral eltrombopag (eltrombopag olamine) (14 days +/- 2 days after initiation of cytarabine) in patients receiving high dose cytarabine and mitoxantrone for the treatment of acute myeloid leukemia patients with hypoplastic bone marrow 14 days +/- 2 days from initiation of cytarabine.

II. To examine platelet count recovery to >= 100 x 10^9/L when eltrombopag is administered following high dose cytarabine and mitoxantrone for the treatment of acute myeloid leukemic patients.

OUTLINE: This is a dose-escalation study.

Patients receive eltrombopag olamine orally (PO) once daily (QD) from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Relapsed/refractory AML patients who received standard of care cytarabine and mitoxantrone as their chemotherapy regimen
  • Patients must either have Grade 4 thrombocytopenia (platelet counts < 25 x 10^9/L) due to chemotherapy unless transfusion within 24-72 hours

  • Current systemic treatment for AML, with the exception of granulocyte colony-stimulating factor (G-CSF) must have been discontinued at least 7 days prior to entry into the study; in addition:

    • At least 4 weeks before Day 1 for interleukin (IL)-11 (oprelvekin)
    • At least 8 weeks before Day 1 for antithymocyte/antilymphocyte globulin
  • Patients with a prior stem cell transplant (SCT) must have failed the SCT
  • Patients must have documented hypoplasia from the bone marrow aspiration and biopsy 14 days +/- 2 days from the initiation of cytarabine treatment schedule (defined as < 5% blasts and < 20% cellularity)
  • Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 2
  • Patient is able to understand and comply with protocol requirements and instructions
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) except for Gilbert syndrome or cases clearly not indicative of inadequate organ function, i.e., elevation of indirect (hemolytic) bilirubin in the absence of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) abnormality
  • ALT and AST =< 3 x ULN
  • Creatinine =< 1.5 x ULN

  • Patient is practicing an acceptable method of contraception (documented in chart); female patients (or female partners of male patients) must either be non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or post-menopausal > 1 year), or of childbearing potential and use 1 of the following highly effective methods of contraception (i.e., Pearl Index < 1.0%) from 2 weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:

    • Complete abstinence from intercourse
    • Intrauterine device (IUD)
    • Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide)
    • Male partner is sterile prior to entry into the study and is the only partner of the female
    • Systemic contraceptives (combined or progesterone only)
  • Demonstrate the ability to swallow and retain oral medication
  • Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Patients with a diagnosis of acute promyelocytic leukemia
  • Patients with a QTcF > 450 msec (QTcF > 480 msec for patients with Bundle Branch Block)
  • AML patients with persistent disease from the recent treatment defined as > 5% blast and/or > 20% cellularity and reported as persistent residual disease by a pathological report of the patient's bone marrow biopsy 14 days +/- 2 days from the initiation of cytarabine
  • Patients with known thrombophilic risk factors; exception: patients for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator
  • Current alcohol or drug abuse
  • Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
  • Active and uncontrolled infections
  • Patients with known active hepatitis B, hepatitis C, or seropositive human immunodeficiency virus (HIV); testing is not required in the absence of clinical suspicion
  • Patients with liver cirrhosis (as determined by the investigator)
  • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or excipient that contraindicates the patients' participation
  • Patients of East Asian ancestry (i.e., Chinese, Japanese, Taiwanese, or Korean)
  • Patients with pre-existing cardiovascular disease (including congestive heart failure, New York Heart Association [NYHA] Grade III-IV), or arrhythmia known to increase the risk or thromboembolic events (e.g., atrial fibrillation)
  • Unwilling or unable to follow protocol requirements
  • Any condition which, in the Investigator's opinion, deems the patient an unsuitable candidate to receive study drug
  • No aspirin (ASA) or nonsteroidal antiinflammatory drugs (NSAIDS) administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01550185

Locations
United States, Georgia
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States, 30322
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Roswell Park Cancer Institute
National Cancer Institute (NCI)
GlaxoSmithKline
Investigators
Principal Investigator: Wetzler Meir Roswell Park Cancer Institute
  More Information

Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT01550185     History of Changes
Other Study ID Numbers: I 206111  NCI-2012-00215 
Study First Received: March 7, 2012
Last Updated: April 4, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Leukemia, Monocytic, Acute
Leukemia, Myelomonocytic, Acute
Hypereosinophilic Syndrome
Leukemia, Basophilic, Acute
Leukemia, Eosinophilic, Acute
Leukemia, Megakaryoblastic, Acute
 Leukemia, Erythroblastic, Acute
Neoplasms by Histologic Type
Neoplasms
Eosinophilia
Leukocyte Disorders
Hematologic Diseases
Myeloproliferative Disorders
Bone Marrow Diseases

ClinicalTrials.gov processed this record on September 28, 2016